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PPARd Is a Type 1 IFN Target Gene and Inhibits
Apoptosis in T Cells
Nadya al Yacoub1, Malgorzata Romanowska1, Sybille Krauss2, Susann Schweiger2,3,4 and John Foerster3,4
Peroxisome proliferator-activated receptor b/d (PPARd) is a nuclear hormone receptor regulating diverse
biological processes, including b-oxidation of fatty acid and epithelial cell differentiation. To date, the role of
PPARd in the immune system has not been thoroughly studied. Here, we show that PPARd is expressed in
activated human T cells purified from peripheral blood as well as in T cells isolated from affected psoriasis skin
lesions. PPARd is induced in T cells on stimulation with type 1 IFN. Functionally, PPARd enhances proliferation of
primary T cells and blocks apoptosis induced by type 1 IFN and by serum deprivation. We show that these
cellular functions are mediated by the activation of extracellular signal-regulated kinase1/2 signaling. Our
results (1) establish a direct molecular link between type 1 IFN signaling and PPARd, (2) define a functional role
for PPARd in human T cells, and (3) suggest that the induction of PPARd by type 1 IFN contributes to the
persistence of activated T cells in psoriasis skin lesions.
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INTRODUCTION
The transcription factor peroxisome proliferator-activated
receptor b/d (PPARd) regulates diverse biological processes,
including adipogenesis, glucose metabolism, myogenesis,
and macrophage function, as well as proliferative responses
involved in colon carcinoma (reviewed in Maisch et al.,
2005; Barish et al., 2006; Burdick et al., 2006). As such, it is
expressed in various cell types, including adipocytes,
endothelial cells, muscle cells, and colon. In the skin, PPARd
is expressed in keratinocytes and contributes to the wound-
healing response (Icre et al., 2006). In keratinocytes, PPARd is
induced by IFN-g, stress-activated kinase, or tumor necrosis
factor (TNF)-a by activator protein-1-mediated transcription
(Tan et al., 2001; Di-Poi et al., 2003).
Psoriasis is a very common chronic inflammatory skin
disease, with an estimated prevalence of 2–4% in white
populations, exhibiting a non-Mendelian pattern of inheri-
tance (Elder, 2005; Rahman and Elder, 2005). Irrespective of
the genetic susceptibility pattern in a given patient, clinical
disease flares are initiated by triggers such as stress and
inflammation, culminating in a common yet complex set of
aberrations involving disturbed keratinocyte proliferation and
differentiation (Gandarillas et al., 1999; Hobbs et al., 2004),
activation of type I IFN signaling, endothelial cell activation,
neutrophil influx, as well as persistence of activated T cells
(Boyman et al., 2004; Kohlmann et al., 2004) and dendritic
cells (Lowes et al., 2005) within the skin. Several lines of
evidence support a role for PPARd in psoriasis pathogenesis:
it is upregulated in lesional psoriatic skin (Westergaard et al.,
2003); is induced by TNF-a, a key cytokine in psoriasis (Tan
et al., 2001; Di-Poi et al., 2003); regulates keratinocyte
differentiation; blocks apoptosis (see below) (Icre et al.,
2006); and induces angiogenesis (Piqueras et al., 2006).
Recently, we showed that the expression pattern of a large
group of transcripts dysregulated in psoriasis is consistent
with the activation of PPARd (Romanowska et al., 2007). We
also showed that activation of PPARd enhances proliferation
of epidermal keratinocytes and that it induces transcription of
heparin-binding epidermal growth factor-like growth factor,
which in turn induces epidermal hyperplasia in vivo (Zheng
et al., 2003; Kimura et al., 2005; Shirakata et al., 2005),
suggesting that activation of PPARd contributes to the
hyperproliferative phenotype in psoriasis, at least in part, by
inducing heparin-binding epidermal growth factor-like
growth factor expression.
On the basis of available evidence, the role of PPARd in
apoptosis appears to be complex and cell type-dependent.
Conflicting data exist in particular with respect to keratino-
cytes. Thus, Di-Poi et al. (2002) reported an inhibitory effect
of PPARd on apoptosis by transcriptional upregulation of
integrin-linked kinase (ILK) and pyruvate dehydrogenase
kinase 1 (PDK1), causing increased phosphorylation of AKT
in murine keratinocytes. The same group also reported
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AKT-dependent protection from ischemia- and H2O2-
induced apoptosis by PPARd in kidney, in vivo and in vitro
(Letavernier et al., 2005). By contrast, none of these effects
could be reproduced by other workers in keratinocytes (Burdick
et al., 2007) or endothelial cells (Liou et al., 2006). Rather, the
latter group identified transcriptional induction of 14-3-3e and,
by implication, inhibited mitochondrial translocation of BAD as
mechanisms underlying protection from H2O2-induced
apoptosis by PPARd in endothelial cells. The inhibition of
oxidative stress-induced apoptosis by PPARd blocking may also
involve induction of catalase (Pesant et al., 2006). A protective
effect by PPARd on celecoxib-induced apoptosis in colon
carcinoma cells has also been shown, although, without
delineation of the mechanism (Shureiqi et al., 2003). To add
another layer of complexity, use of less specific agonists, such as
prostacycline, has even led to the suggestion of proapoptotic
activity by PPARd in 293T and endothelial cells, although the
mechanism underlying this effect remain obscure.
In light of diverse activities of PPAR isoforms in various
inflammatory processes, their expression and functional role
in T cells are not surprising. Thus, PPARg acts proapoptoti-
cally in T cells (Harris and Phipps, 2001, 2002; Cippitelli
et al., 2003; Soller et al., 2006). PPARa, in turn, appears to
counter proinflammatory signaling in T cells, including the
activation of IL-2, c-jun, and NFkB (Jones et al., 2002, 2003;
Dunn et al., 2007). Surprisingly, very little is known about the
expression and function of PPARd in T cells. Here, we report
that PPARd is expressed in primary human T cells as well as
in T cells derived from active psoriasis and that PPARd is a
direct target gene of type 1 IFN. PPARd blocks IFN-induced
apoptosis in T cells. Our results establish a direct link
between IFN and PPARd signaling and identify an important
function of PPARd in a key cell type involved in psoriasis.
RESULTS
PPARd is expressed in activated T cells
We analyzed expression of PPARd in human T-cell
populations from peripheral blood and from psoriasis skin
lesions, as PPARd plays a role in psoriasis, a disease involving
activated T cells, and other PPAR isoforms are expressed in T
cells. As shown in Figure 1a, we detected expression of
PPARd both at the mRNA and the protein levels in CD3þ
T cells isolated from peripheral blood, the Jurkat T cell line,
as well as CD3þ T cells isolated from active psoriasis
plaques. In each case, PPARd protein was localized almost
exclusively to the nucleus. As the expression level was
highest in the T cells from psoriasis, which are activated, we
next tested whether PPARd expression can be induced by
TCR stimulation. To this end, we purified peripheral T cells
from buffy coat of healthy probands by magnetic-activated
cell sorting-mediated negative depletion of CD19, CD14,
CD16, and CD56 lineages and exposed them to stimulatory
anti-CD3 antibody either added to the medium, or precoated
to the bottom of the culture dishes for 48 hours. We did not
observe induction of PPARd in cells from three donors using
this protocol (data not shown). Moreover, co-incubation with
concanavalin A also only led to a marginal induction of
PPARd (Figure 2a). Therefore, TCR stimulation does not cause
induction of PPARd in peripheral human T cells.
PPARd is a transcriptional target of type I IFN
We next used CD3þ human T cells isolated from peripheral
blood to screen for induction of PPARd expression by various
agents. As shown in Figure 2a, robust nuclear accumulation
of PPARd protein was induced, as expected, after stimulation
with TNF-a, presumably acting through a previously char-
acterized cascade involving activator protein-1 signaling (Tan
et al., 2001). In contrast, IL-2, or concanavalin A, had no
significant effect on PPARd expression. Two proapoptotic
stimuli, anti-Fas and hydrogen peroxide, also strongly
induced PPARd. As IFNs also regulate apoptosis, we
stimulated T cells with IFN-a (type 1) and IFN-g (type 2).
Only IFN-a, but not IFN-g, strongly induced PPAR expression
in primary T cells. Given the pivotal role of type 1 IFN in
psoriasis, and the strong upregulation of PPARd in this disease
in vivo, we characterized the induction of PPARd by type 1
IFN in further detail. As shown in Figure 2b, induction of
PPARd by type 1 IFN at the mRNA level could not be
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Figure 1. Expression of PPARd in human T cells. Detection of PPARd by reverse-transcription PCR (RT-PCR) (top) and western blot (bottom) in T cells
expanded from psoriasis lesions, CD3þ T cells isolated from peripheral blood, and Jurkat T cells. For analysis of protein expression, nuclear (n) and cytosolic
(c) fractions were prepared as specified in Materials and Methods and subjected to SDS-PAGE and western blot using 20 mg per lane of cytosolic (c) or nuclear
(n) fraction. A Ponceau S stain of the blots is shown at the bottom for control of protein loading.
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prevented by blocking de novo protein translation using
cycloheximide, suggesting a direct transcriptional effect. The
stimulatory effect observed on incubation with cyclohexi-
mide alone is presumably mediated through the induction of
IFN-b (Maroteaux et al., 1983; Ringold et al., 1984). Direct
transcriptional induction of PPARd by type 1 IFN was also
supported by a time-course study, showing notable transcrip-
tional induction at 6 hours and maximal induction at 12 hours
after stimulation (Figure 2c). Interestingly, we observed
pronounced differences in the magnitude of PPARd induction
by IFN-a in T cells from various individuals. These differences
were closely correlated with the level of PPARd expression
before stimulation, such that cells harboring high endogenous
PPARd levels showed less upregulation by IFN-a (Figure 2d;
r¼0.92). Taken together, PPARd is regulated in primary
human T cells, as in other cell types, by TNF-a and apoptotic
and stress signals, but in addition also by type 1 IFN.
PPARd stimulates T-cell proliferation
We next sought to address the functional role of PPARd in
T cells. As proliferation and apoptosis are two cellular
processes regulated by PPARd in other cell types, we studied
these in human T cells. As shown in Figure 3a, activation of
PPARd by the specific synthetic ligand L-165041 enhanced
the proliferation of Jurkat T cells. Conversely, cellular
proliferation was inhibited in cells on RNA interference
(RNAi)-mediated knockdown of PPARd (Figure 3b). Similarly,
the fraction of T cells harboring a PPARd-specific RNAi
construct decreased by threefold after 4 days in culture, but
not in cells harboring control lentivirus (Figure 3c), demons-
trating a proliferative disadvantage in PPARd-deficient T cells.
Thus, PPARd enhances proliferation in human T cells.
PPARd protects from IFN-a-induced apoptosis
Having identified PPARd as a type 1 IFN target in human
T cells, we examined whether it regulates the effect of type 1
IFN on T-cell apoptosis. As shown in Figure 4a, knockdown
of PPARd in human Jurkat T cells increased the rate of
spontaneous apoptosis by approximately twofold from 18 to
33%, as measured by the frequency of annexin Vþ cells.
Culturing of Jurkat cells in the presence of IFN-a after
infection with empty control lentivirus modestly increased
the frequency of annexin Vþ cells. By contrast, apoptosis
dramatically increased from 33 to 65% on IFN-a stimulation
after lentivirus-mediated knockdown of PPARd. Conversely,
activation of endogenous PPARd in Jurkat cells by the PPARd-
specific synthetic ligand L-165041 was able to completely
inhibit the (B2-fold) increase in apoptotic cells on IFN-a
stimulation (Figure 4b). To verify this effect in primary human
cells, we infected phytohemagglutinin-activated CD3þ T
cells from peripheral blood either with PPARd RNAi lentivirus
or empty control virus. Weak annexin V staining was evident
in approximately 35% and strong annexin V staining in
approximately 10% of infected cells, indicative of cellular
stress caused by the infection with lentivirus (Figure 4c, upper
middle panel). Stimulation with IFN-a caused a significant
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Figure 2. Induction of PPARd expression in naı¨ve primary human T cells. (a) CD3þ T cells were purified from PBMCs using magnetic-activated cell
sorting-mediated negative depletion as detailed in Materials and Methods. Subsequently, cells were incubated for 48 hours with either IL-2 (40 ng ml1), INF-a
(200 ng ml1), anti-Fas (20 ng ml1), concanavalin A, H2O2 (1 mM), INF-g (20 ng ml
1), or TNF-a (20 ng ml1), as indicated. Nuclear (N) and cytosolic (C)
fractions were then subjected to SDS-PAGE and western blot. Per lane, 20mg of extract was loaded. (b) Naı¨ve primary CD3þ T cells were stimulated with
INF-a cultured for 48 hours in the presence or absence of cycloheximide (5 mM). PPARd mRNA expression was analyzed by RT-PCR. Glyceraldehyde-
3-phosphate dehydrogenase was used as the internal control to confirm equal amounts of cDNA loading. (c) Naı¨ve primary CD3þ T cells were treated
with 200 ng ml1 INF-a for the time points indicated. PPARd expression was analyzed by RT-PCR as outlined in (b). (d) Naive primary CD3þ T cells
from six healthy donors were stimulated with INF-a for 12 hours, followed by analysis of PPARd RNA expression by PCR. Expression was quantitated
densitometrically and normalized to glyceraldehyde-3-phosphate dehydrogenase expression. Data shown represent results from five separate donors.
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increase in annexin Vbright staining cells (from 11 to 18%)
only after PPARd knockdown, but not in control virus-
infected cells, suggesting that PPARd inhibits type 1 IFN-
induced apoptosis in primary human T cells.
PPARd protects from serum withdrawal- but not Fas-induced
apoptosis
Apoptosis mediated by serum withdrawal proceeds through
bypassing the activation of the death-inducing signaling
complex triggered by Fas. To elucidate which of these
proapoptotic pathways are regulated by PPARd in T cells, we
infected Jurkat T cells with PPARd knockdown or control
lentivirus and subjected them subsequently to either serum
deprivation or stimulation with anti-Fas antibody. Detection
of early apoptotic cells was then performed by annexin V
staining, whereas cells with reduced DNA content (sub-G1)
or advanced DNA fragmentation were visualized by
propidium iodide DNA staining in fixed cells. As shown in
Figure 5 (panels labeled ‘‘normal medium’’), knockdown of
PPARd alone, in the absence of further treatments, resulted in
an approximately twofold increase in early apoptotic annexin
Vþ (11.1 vs 7.6%) and sub-G1 (61 vs 29%) cells, confirming
the results described above. Serum withdrawal increased the
percentage of annexin Vþ cells by twofold after PPARd
knockdown, but not in cells harboring control lentivirus.
Similarly, the frequency of cells exhibiting advanced DNA loss
was twofold higher after PPARd knockdown than in controls
cells (66 vs 39%; Figure 5b). Remarkably, G1- and G2/S-phase
cells all but disappeared after PPARd knockdown, suggesting a
potent protective effect of PPARd on apoptosis mediated by
serum deprivation. Upon Fas activation, Jurkat T cells stained
uniformly with annexin Vbright (Figure 5a, panels on right),
corresponding to a marked accumulation of sub-G1, but not
advanced fragmented cells (Figure 5b), regardless of the
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Figure 3. PPARd enhances T-cell proliferation. (a) Jurkat T cells were grown in the presence of 1 mM PPARd-specific ligand L-165041 (shaded columns)
or vehicle (black). Cell number was determined by counting at the indicated time points. Data shown represent mean±SD of three independent experiments,
each performed in duplicate. *Po0.001 in a two-sided paired t-test. (b) Jurkat T cells were infected with PPARd-RNAi lentivirus (black symbols) or empty
control virus (gray). Cellular proliferation was assessed by MTS-colorimetric conversion, as described in Materials and Methods, at the indicated time
points. Data shown represent mean and SD of the quintuplicate determinations. Two independent experiments showed comparable results. *Po0.001 in a
two-sided paired t-test. (c) Jurkat T cells were infected with control lentivirus (pLL3.7) or lentivirus harboring a PPARd-specific siRNA sequence (PPARdRNAi).
The frequency of infected cells was determined by FACS analysis of the GFP reporter gene. The percentage of infected cells is shown in the figure.
(d) Western blot of Jurkat T cells 48 hours after infection with lentivirus, as specified in (b). Ponceau S staining of the blot is shown for verification of even
protein loading. cyt, cytosolic fraction; nuc, nuclear fraction.
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presence of PPARd. Thus, PPARd blocks apoptosis induced by
serum deprivation but not by Fas activation.
Mechanism of antiapoptotic PPARd activity in T cells
The antiapoptotic role of PPARd in keratinocytes has been
suggested to proceed by transcriptional activation of PDK and
ILK1 (Di-Poi et al., 2002), although this could not be
reproduced by other investigators (Burdick et al., 2007). In
T cells, we were unable to detect any transcriptional up- or
downregulation of either kinase upon PPARd activation by
synthetic ligand, or on PPARd knockdown (Figure 6a and b).
The results shown above suggest that apoptosis induced by
growth factor deprivation through serum withdrawal is
inhibited by PPARd. As the antiapoptotic action of growth
104103102101100
104103102101100
104103102101100 104103102101100
104103102101100
104103102101100104103102101100
104103102101100104103102101100
104103102101100104103102101100
104103102101100104103102101100
104103102101100
104103102101100
104103102101100
GFP
pLL3.7
Annexin-V
Annexin-V
Annexin-V
38
18%
00
0
100
100
100
Co
un
ts
Co
un
ts
Co
un
ts
0
100
Co
un
ts
32
11%
PPARδRNAi
PPARδRNAi
43 8%
Control
58
9%
IFNα
IFNα
IFNα
14%
0
150
Co
un
ts
Co
un
ts
Co
un
ts
Co
un
ts
16%
0
150
0
150
Co
un
ts
Co
un
ts
L165041
DMSO
14%
Control
0
150
29%
65%
0
200
Co
un
ts
0
200
33%
0
200
Co
un
ts
0
200
GFP
GFP
26%16%
Control
pLL3.7
a
b
c
Figure 4. PPARd protects from INF-a-induced apoptosis. (a) Jurkat T cells were infected with empty control lentivirus (pLL3.7) or lentivirus harboring a
PPARd-specific siRNA sequence, as indicated in the figure. Infection was confirmed by FACS of the enhanced GFP reporter, as shown on the left. Forty-eight
hours after infection, the cells were cultured in the presence or absence of INF-a for an additional 48 hours. Cells were then stained with annexin V-Cy5,
followed by FACS analysis of GFP-positive cells. Annexin V-positive cells are indicated by the horizontal bar. (b) Jurkat T cells were stimulated with INF-a for
48 hours in the presence of 1 mM of the PPARd-specific ligand L-165041 or vehicle (DMSO), followed by quantification of annexin Vþ cells as outlined in (a).
(c) Primary T cells were isolated from peripheral blood using a stimulatory CD3 antibody, as detailed in Materials and Methods, processed as in (a). For
quantification of annexin Vþ cells, lentivirus-infected cells were gated by FACS of the GFP reporter, as shown on the left. Comparable results were obtained
in CD3þ cells from three independent healthy donors.
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factors contained in serum is mediated through the activation
of extracellular signal-regulated kinase (ERK)1/2 signaling, we
studied ERK1/2 phosphorylation in Jurkat T cells infected with
PPARdRNAi or control lentivirus. As shown in Figure 6c, serum
withdrawal led to a strong increase in ERK1/2 phosphoryla-
tion, an antiapoptotic response that has been noted pre-
viously (Erhardt, Mol Cell Biol; 1999 and Narita, J Biol
Chem). By contrast, PPARd knockdown completely blocked
ERK1/2 phosphorylation. Furthermore, stimulation of Jurkat
cells with IFN-a led to notable phosphorylation of nuclear
ERK1/2 only after concurrent activation of PPARd with the
synthetic ligand, but not in the absence of PPARd activation.
Thus, the protective effect of PPARd on IFN-a and serum
withdrawal-induced apoptosis in T cells is mediated, at least
in part, by enhanced activation of ERK1/2.
DISCUSSION
This study identifies PPARd as a target gene of type 1 IFN in
T cells. Available evidence suggests that transcriptional
regulation of PPARd is complex and cell type-dependent. In
murine keratinocytes, PPARd is induced by TNF-a and IFN-g
by activation of an activator protein-1-binding site, and
repressed by CCAAT/enhancer-binding protein isoforms and
Smad3 (Tan et al., 2001, 2004; Di-Poi et al., 2005). This
pathway has not been confirmed in primary human
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Figure 6. Phosphorylation of ERK1/2, but not expression of ILK and PDK1
kinases, is regulated by PPARd in T cells. (a) Jurkat T cells were stimulated
with 1 mM L-165041 or vehicle (DMSO) for 48 hours. The expression of PDK1
and ILK1 was analyzed by RT-PCR. (b) Jurkat T cells were infected with
control lentivirus (pLL3.7) or lentivirus harboring a PPARd siRNA sequence
(PPARdRNAi). Forty-eight hours after infection, the expression of PPARd, ILK1,
and PDK1 was analyzed by RT-PCR. (c) Jurkat cells were infected as in (b),
followed by serum withdrawal (SF) or incubation in normal medium (RPMI)
for 24 hours. Western-blot analysis was performed using whole-protein
extracts. (d) Jurkat T cells were treated with 200 ng ml1 INF-a in the presence
or absence of PPARd-specific ligand GW-501516 for 24 hours. Western blots
were performed using nuclear protein extracts.
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keratinocytes, but there may exist species differences,
as PPARd is expressed in human, but not murine,
adult interfollicular epidermis. In human colorectal
cancer cell lines, it is regulated by b-catenin through a
T-cell factor/lymphoid enhancer factor site (He et al.,
1999), whereas it is induced by vitamin D/retinoid X
receptor heterodimers (Dunlop et al., 2005) in several
human epithelial cell lines. Although the induction
through TNF-a in T cells reported here presumably proceeds
through the previously characterized mechanism, the
cis-acting elements that are operative downstream of type 1
IFN and TCR activation remain to be determined. In silico
analysis of the human PPARd promoter predicts several
candidate IFN-stimulated response elements and nuclear
factor of activated T cell elements. Clearly, more studies are
needed to define the transcriptional regulation of PPARd in
T cells in detail.
The data presented here show that PPARd blocks apoptosis
induced by serum withdrawal. Growth-factor deprivation by
serum withdrawal was chosen to further characterize the role
of PPARd in apoptosis, as this pathway has been reported to
be regulated by PPARd in keratinocytes (Di-Poi et al., 2002).
Our results show that PPARd is indeed required for protection
from growth-factor deprivation-induced apoptosis, but not by
Fas-induced apoptosis in T cells. This activity is, at least in
part, mediated by ERK1/2 phosphorylation. It is likely that the
activation of ERK1/2 signaling also contributes to the
stimulation of T-cell proliferation, which we observed.
Possibly, activation of ERK1/2 signaling by PPARd is cell
type-dependent, as it has not been observed in keratinocytes
(Burdick et al., 2007). As ERK1/2 phosphorylation occurs
also in response to oxidative stress (Hill et al., 2006), the
induction of PPARd by hydrogen peroxide observed here
(Figure 2) may not only protect from oxidative stress-induced
apoptosis by induction of catalase (Pesant et al., 2006), but
also by activation of ERK1/2. Taken together, PPARd appears
to act as an activator of ERK1/2 signaling in response
to extracellular stress.
Concerning the mechanism of action, although the present
data show that the induction of PPARd by IFN-a causes
activation of ERK1/2 (Figure 5d), this may not be the only
mechanism underlying the modulation of type 1 IFN
signaling. Thus, the inhibition of apoptosis in T cells may
involve preferential signaling of type 1 IFN through signal
transducer and activator of transcription (STAT)3 as opposed
to STAT1 or STAT2 (Tanabe et al., 2005). In human T-cell
leukemia cells, STAT3 phosphorylation blocks apoptosis
by transcriptional induction of the bcl-2 member Mcl-1
(Epling-Burnette et al., 2001). We did not observe transcrip-
tional effects of PPARd on the levels of any STAT isoform
either in primary T cells or Jurkat cells (data not shown).
However, an indirect regulation of STAT3 function
by PPARd is conceivable. Thus, activation of PPARg,
which acts antagonistically to PPARd in many biological
processes, enhances apoptosis and causes dephosphorylation
of STAT3 (Kim et al., 2005). Taken together, several
cellular actions may be involved in the antiapoptotic activity
of PPARd.
The inhibition of IFN-a-induced apoptosis in T cells by
PPARd raises a number of intriguing questions about the role
of PPARd in the regulation of T-cell survival in vivo (Marrack
and Kappler, 2004). Thus, it is conceivable that the induction
of PPARd contributes to the antiapoptotic effect of type 1 IFN
on activated T cells previously observed in mice (Marrack
et al., 1999). Apart from modulating IFN signaling, PPARd
may affect activation-induced cell death (Hildeman et al.,
2002), possibly by linking T-cell activation to metabolic state
(Chinetti et al., 2000; Kostadinova et al., 2005). Therefore, a
more detailed analysis of chronic PPARd activation on the
persistence of activated T cells in vivo is warranted.
Currently, activation of PPARd in vivo by synthetic ligands
is being evaluated in clinical trials as a potential long-term
treatment for metabolic syndrome (Chang et al., 2007;
Sprecher et al., 2007). An increased steady-state level of
activated T cells observed after prolonged drug-induced
PPARd activation would necessitate a re-appraisal of this
treatment approach.
Finally, these data represent previously unknown evidence
for a contribution of PPARd to the pathogenesis of psoriasis.
Recently, we showed that PPARd is highly upregulated in
psoriasis lesions and stimulates the proliferation of epidermal
keratinocytes (Romanowska et al., 2007). Apart from
keratinocyte proliferation, the activation of type 1 IFN
signaling and the persistence of activated CD8þ T cells are
additional key features of this complex disease. Strikingly,
increased phosphorylation of ERK1/2 has recently been
discovered in active psoriasis lesions (Johansen et al.,
2005). Therefore, the current results indicate that induction
of PPARd by type 1 IFN contributes to the prolonged survival
of activated T cells in psoriatic skin by activation of ERK.
PPARd-mediated ERK activation also antagonizes PPARg, as
this isoform has a proapoptotic effect in T cells (Harris and
Phipps, 2001, 2002) and is directly inhibited by ERK-
mediated phosphorylation (Hu et al., 1996). Consistent with
this notion, activation of PPARg has an inhibitory effect on
psoriasis, whereas this is not the case with PPARd activation
(Kuenzli and Saurat, 2003; Malhotra et al., 2005). Finally,
PPARd expression has been detected in dendritic cells
(Jakobsen et al., 2006) and its activation stimulates angiogen-
esis in endothelial cells (Piqueras et al., 2006). Thus, PPARd
affects several cell populations critical for psoriasis pathogen-
esis and its inhibition may represent a promising approach for
drug development.
MATERIALS AND METHODS
Patients and skin samples
All experiments with samples obtained from patients were carried
out in accordance with the Declaration of Helsinki Principles.
Patients undergoing biopsy gave a written statement of consent
subject to prior approval by the Charite´ Institutional Review Board
and were undergoing in-patient treatment for active disease at the
time of sampling. Full-thickness excisional biopsies approximately
3 cm2 in diameter were processed as described (Kohlmann
et al., 2004). Briefly, samples were trimmed off fatty tissue, rinsed
in prewarmed phosphate-buffered saline (PBS), cut into approxi-
mately 2 mm pieces, and placed in AIM-V medium including
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penicillin/streptomycin and 5% human serum. Cells emigrating from
the tissue scaffolds were first re-seeded in 96-well round-bottomed
plates and, on outgrowth of T-cell lines, expanded on flat-bottomed
plates in the presence of 40 ng ml1 IL-2 (Falcon, Heidelberg,
Germany, no. 353077).
Reagents
Human INF-a and INF-g were obtained from PBL Biomedical
Laboratories, Reutlingen, Germany (no. 11100-1). Recombinant
human TNF-a was from PeproTech, Hamburg, Germany (no. C-300001-
ASS). Anti-CD123-FITC, CD19-MicroBeads, CD14-MicroBeads,
a-CD16-FITC, CD3-MicroBeads, and anti-FITC-MicroBeads were
purchased from Miltenyi Biotec (Bergisch Gladbach, Germany).
Annexin V-Cy5 and anti-CD56-FITC were obtained from BD
Biosciences (Heidelberg, Germany). Anti-p44/42 (ERK1/2) and
anti-phospho-p44/42 (no. 877-616) were obtained from Cell
Signalling (Frankfurt, Germany). Phytohemagglutinin-A and H2O2
were from Sigma-Aldrich (Munich, Germany). The selective PPARd
agonist L-165041 (Calbiochem, no. 422175) was diluted and
aliquoted in DMSO under N2 atmosphere. Cells were stimulated
with 1mM L-165041 for the time span specified in the Results section.
Medium with fresh L-165041 was added every 24 hours for longer
stimulations. Control cells received identical volume of vehicle
(0.05% vol/vol final DMSO).
Isolation and maintenance of T cells from peripheral blood
mononuclear cells
Peripheral blood mononuclear cells (PBMCs) were isolated using
density-gradient centrifugation with Ficoll-Paque from venous blood
collected from healthy donors. Activated CD3þ T cells were
isolated from PBMCs by positive selection using CD3-stimulatory
MACS MicroBeads (Miltenyi Biotec, no. 130-050-101) according to
standard procedures. Naive, unstimulated CD3þ T cells were
isolated by magnetic microbead-mediated depletion of CD14-,
CD19-, CD123-, CD56-, and CD16-positive cells from PBMCs. For
each depletion, two consecutive adsorptions to LSþ columns
(Miltenyi Biotec) were used. Purity of the resulting CD3þ cell
fraction was quantified by FACS detection of CD3 and was greater
than 93% in all cases. Purified primary T cells were cultured in AIM-
V medium (Gibco, Mannheim, Germany, no. 12055) supplemented
with 5% human serum (PAN Systems, no. P30-2401), 1% penicillin/
streptomycin (Gibco, no. 15140-122), and 40 U ml1 IL-2 (Promo-
Kine, Heidelberg, Germany, no. C-61240) at 371C and 5% CO2 in
sixwell plates. For activation, negatively sorted T cells were cultured
for 16 hours with phytohemagglutinin (5 mg ml1). The human T-cell
line Jurkat (obtained from DSMZ, Heidelberg, Germany, no.
ACC282) was cultured in RPMI-1640 medium with 10% fetal calf
serum and 1% penicillin/streptomycin at 371C and 5% CO2.
Reverse-transcription PCR
Total RNA was isolated using the NucleoSpin II extraction kit
(Machery-Nagel, no. 740955) and cDNA, which was synthesized
using reagents purchased from Invitrogen (Mannheim, Germany).
The primers used for PCR were glyceraldehyde-3-phosphate
dehydrogenase: sense, 50-gtcagtggtggacctgacct-30 and anti 50-aggggt
ctacatggcaactg-30 (product: 420 bp); PPARd: sense, 50-aactgcagatggg
ctgtaac-30 and anti, 50-gtctcgatgtcgtggatcac-30(483 bp), PDK: sense,
50-ggttgggaaccactctttca-30, anti, 50-ttgtgcaataggccatgtgt-30(532 bp);
and ILK: sense, 50-atcacacactggatgccgta-30 and anti, 50-cttccaatgcca
ccttcatt-30(500 bp). Amplification conditions were as follows: for
glyceraldehyde-3-phosphate dehydrogenase, annealing at 551C and
25 cycles; for PPARd, 541C and 28 cycles; for PDK and ILK, 551C
and 28 cycles.
Western blotting
Cells were seeded in sixwell plates at a density of 106 ml1 and
treated for 48 hours with the reagents specified under Results. Cells
were harvested, washed with PBS, and the pellet was frozen in liquid
N2. The NE-PER Extraction Kit (Pierce, Waldbronn, Germany,
no. 78833) was used to prepare the nuclear and cytoplasmic
fractions. Protein concentration was determined using the BCA kit
(Pierce, no. 23225). Samples were diluted with tricine sample buffer
(Bio-Rad, no. 161-0739) and boiled at 951C for 10 minutes. Per lane,
20 mg protein was loaded on 7.5% SDS-PAGE. After transferring to
nitrocellulose membranes (Schleicher & Schell, no. 23225), blots
were stained with Ponceau red and blocked with 4% non-fat milk in
TBST (Tris-buffered saline with 0,05% Tween 20) for 30 minutes at
room temperature (RT). Subsequently, blots were incubated with
anti-human PPARd (Cayman Chemical, no. 101720) diluted at 1:300
in 4% milk/TBST overnight at 41C. After washing 3 times with TBST,
blots were incubated with anti-rabbit IgG-horseradish peroxidase
(dilution 1:2,000; Amersham, Dreieich, Germany, NA934) at RT.
Detection was performed using the ECL Plus western blotting
detection system (Amersham, no. RPN2132) on a CCD system.
Whole-cell protein extracts were prepared by washing cells twice
with ice-cold PBS followed by lysis in ice-cold lysis buffer (0.01 M
Tris-HCl, pH 7.5; 0.144 mol l1 NaCl; 0.5% Nonidet P-40; 0.5%
SDS; 0.1% aprotinin; 10 mg ml1 leupeptin; 2 mM phenylmethane-
sulfonyl fluoride; and 5mg ml1 pepstatin). Insoluble aggregates were
removed by centrifugation.
Generation of lentivirus and infection of cells
Production of VSV-G pseudotyped replication-deficient lentivirus
was carried out as described in Yacoub et al. (2007). For infection of
primary T cells, CD3þ purified cells were activated with
phytohemagglutinin for 16 hours and then propagated in AIM-V
medium with IL-2 for 7 days. Subsequently, cells were
washed, harvested, and resuspended at 3 106 ml1. A volume of
100ml of cell suspension was mixed with a maximum of 2 ml
virus-containing supernatant to obtain a multiplicity of infection
of 10. After adding polybrene to a final concentration of 8 mg ml1,
the virus–cell mix was spun for 1 hour at 2,000 r.p.m. at RT.
After incubating cells at 371C for 3 hours, spin infection was
repeated once. Cells were plated in the virus-containing medium,
which was replaced 12 hours later. The efficiency of infection was
verified in each case using FACS detection of the enhanced green
fluorescent protein (GFP) reporter, as shown in the respective figures
in the Results section.
Proliferation assay
Cells were plated at 2 104 per well in 96-well plates in
100ml RPMI medium containing 10% fetal calf serum. At the time
points indicated under Results, cells were incubated with the MTS
reagent (Promega, Heidelberg, Germany) for 1 hour at 371C, as
instructed by the manufacturer, followed by detection of absorbance
at 490 nm.
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Analysis of sub-G1 cells and annexin V staining
Cells to be analyzed (8 105 per sample) were washed twice with
PBS and fixed in 5 ml cold 70% ethanol at 41C for 1 hour. After
washing with PBS, cells were treated with 0.1 mg RNaseA (Sigma-
Aldrich, no. R 4875) at 371C for 30 minutes in 400 ml PBS. After
addition of propidium iodide (20 mg ml1), samples were incubated
for an additional 30 minutes at RT. After washing, the samples were
resuspended and fluorescence was determined by FACS. For
enhanced differentiation between sub-G1 cells and cells exhibiting
advanced DNA fragmentation, fluorescence detection was acquired
using log scale rather than linear settings. As S- and G2-phase cells
were only partially resolved using these settings, they were
quantified in a common region, as indicated in the Results section.
For detecting early apoptotic cells, staining with annexin V-Cy5 was
performed. Cells were collected, washed twice with PBS, and
1 105 cells were resuspended in 100 ml of 1 binding buffer
(10 binding buffer: 0.1 M HEPES, pH 7.4, 1.4 M NaCl,
25 mM CaCl2). Next, 5ml annexin V-Cy5 was added, and cells were
incubated for 15 minutes at RT in the dark. After addition of 300 ml of
1 binding buffer, cells were analyzed by FACS on the FL-2
channel in a FACSCalibur machine.
Induction of apoptosis
Jurkat cells or peripheral blood-derived CD3þ T cells were infected
with lentivirus and cultured as specified above. Forty-eight hours
after infection, cells were either serum-deprived or exposed to anti-
Fas (Upstate Biotech, Schwalbach, Germany, no. 05-201) at a final
concentration of 20 ng ml1, or both, as specified in the Results
section.
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